登录 | 注册    关注公众号  
微信公众号
搜索
 > 【Angiopoietin-like 3】

Angiopoietin-like 3信息

英文名称:Angiopoietin like 3
中文名称:血管生成素样蛋白-3
靶点别称:Angiopoietin Like 3,Angiopoietin 5,UNQ153/PRO179,Angiopoietin-5,Angiopoietin-like protein 3,ANGPT5,ANG-5,Angiopoietin-Related Protein 3,Angiopoietin-Like 3,FHBL2,ANL3,ANGPTL3
上市药物数量:1
临床药物数量:4
最高研发阶段:批准上市

Angiopoietin-like 3产品列表

 
评论(2)
AN3-H5226|Human Angiopoietin-like 3 / ANGPTL3 Protein, His Tag
  1. 139XXXXXXX3
  2. 0人赞
  3. 该产品给我们带来了不一样的实验结果,对我们的对比实验结果有很好的说明,价格公道,质量可靠,为我们的实验提供了完美的说服力。
  4. 2022-06-25
AN3-H52H3|Human Angiopoietin-like 3 / ANGPTL3 Protein, His Tag
  1. 139XXXXXXX3
  2. 0人赞
  3. 因为这种蛋白质可能在血管生成的调节中发挥作用。我们主要研究血管生成素样3蛋白与整合素进行结合实验,效果很不错
  4. 2022-06-25
 

Angiopoietin-like 3 分子别名

ANGPTL3,ANGPT5,ANG-5,Angiopoietin-5,FHBL2

Angiopoietin-like 3 分子背景

Angiopoietin-like protein 3 (ANGPTL3) is also known as Angiopoietin-related protein 3, Angiopoietin-5 (ANGPT5 / ANG-5), is a member of the angiopoietin-like family of secreted factors. ANGPTL3 / ANGPT5 is predominantly expressed in the liver, and has the characteristic structure of angiopoietins, consisting of a signal peptide, N-terminal coiled-coil domain and the C-terminal fibrinogen (FBN)-like domain. The FBN-like domain in angiopoietin-like 3 protein was shown to bind alpha-5/beta-3 integrins, and this binding induced endothelial cell adhesion and migration. This protein may also play a role in the regulation of angiogenesis. Angptl3 also acts as dual inhibitor of lipoprotein lipase (LPL) and endothelial lipase (EL), and increases plasma triglyceride and HDL cholesterol in rodents. ANGPTL3 inhibit endothelial lipase to catalyze HDL-phospholipid and increase HDL-PL levels. Circulating PL-riched HDL particles have high cholesterol efflux abilities.

Angiopoietin-like 3 前沿进展

Angiopoietin-like 3上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验
Evinacumab REGN-1500 批准上市 Regeneron Pharmaceuticals Inc Evkeeza EU 高胆固醇血症 Regeneron Ireland Designated Activity Company 2021-02-11 纯合子家族性高胆固醇血症, 高胆固醇血症 详情

Angiopoietin-like 3临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
LY-3475766 LY-3475766 礼来制药 详情
ARO-ANG3 ARO-ANG3 临床二期 Arrowhead Pharmaceuticals 纯合子家族性高胆固醇血症, 高甘油三酯血症, 血脂障碍, II型高脂蛋白血症 详情
Vupanorsen ISIS-703802; PF-07285557 临床二期 Ionis Pharmaceuticals Inc 高甘油三酯血症, 纯合子家族性高胆固醇血症, 非酒精性脂肪肝, 二型糖尿病, I型高脂蛋白血症, 高脂蛋白血症, 血脂障碍, 心脏和血管疾病, II型高脂蛋白血症, 高脂血症 详情
LNA-043 LNA-043 临床二期 诺华制药 膝盖受伤, 膝关节炎, 骨关节炎, 创伤和损伤 详情
ARO-APOC3 ARO-APOC3 临床三期 Arrowhead Pharmaceuticals 高甘油三酯血症, I型高脂蛋白血症, 血脂障碍 详情
LY-3561774 LY-3561774; DCR-CM-1; DCR-CM1 临床二期 Dicerna Pharmaceuticals 代谢病, 血脂障碍, 高脂蛋白血症, 心脏和血管疾病, 脂类代谢紊乱 详情

消息提示

请输入您的联系方式,再点击提交!

确定